{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=61",
    "query": {
      "intervention": "Experimental 2",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 4119,
    "total_pages": 412,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+2&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T12:28:57.154Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis",
        "Post-PV MF",
        "Post-ET Myelofibrosis",
        "Primary Myelofibrosis",
        "MF"
      ],
      "interventions": [
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        },
        {
          "name": "Navtemadlin placebo",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-06-03",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06479135"
    },
    {
      "nct_id": "NCT05573126",
      "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor-positive Breast Cancer",
        "Hormone Receptor Positive HER-2 Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "EP0062",
          "type": "DRUG"
        },
        {
          "name": "Elacestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ellipses Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2023-01-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05573126"
    },
    {
      "nct_id": "NCT05194397",
      "title": "Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Cancer Survivors",
        "Aplastic Anemia",
        "Myelodysplastic Syndromes",
        "Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Riboside",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "10 Years to 30 Years"
      },
      "enrollment_count": 80,
      "start_date": "2023-02-23",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194397"
    },
    {
      "nct_id": "NCT04702750",
      "title": "Reactivating Specific Memories During Sleep in Conjunction with a Suppression Context",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep",
        "Consolidation"
      ],
      "interventions": [
        {
          "name": "Targeted memory reactivation (odors)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Targeted memory reactivation (sounds)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 23,
      "start_date": "2022-02-10",
      "completion_date": "2024-05-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04702750"
    },
    {
      "nct_id": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Squamous Cell Carcinoma of the Anus",
        "Squamous Cell Carcinoma of the Cervix",
        "Squamous Cell Carcinoma of the Skin",
        "Renal Cell Carcinoma",
        "Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Mismatch Repair Deficient or MSI-High Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SL-279252",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shattuck Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-03-26",
      "completion_date": "2023-05-04",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894618"
    },
    {
      "nct_id": "NCT02658890",
      "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Melanoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 627,
      "start_date": "2016-04-14",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • La Jolla, California • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658890"
    },
    {
      "nct_id": "NCT02383420",
      "title": "Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Carestream Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2015-02",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-15",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383420"
    },
    {
      "nct_id": "NCT03985982",
      "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Croma-Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 410,
      "start_date": "2019-04-29",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985982"
    },
    {
      "nct_id": "NCT04427982",
      "title": "Dance and Diabetes/Prediabetes Self-Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Pre Diabetes"
      ],
      "interventions": [
        {
          "name": "dance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "diabetes education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-09-03",
      "completion_date": "2021-05-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04427982"
    },
    {
      "nct_id": "NCT01156376",
      "title": "Oral Irritation Study of Two Experimental Mouthrinses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oral Manifestations"
      ],
      "interventions": [
        {
          "name": "Potassium Oxalate without Fluoride",
          "type": "DEVICE"
        },
        {
          "name": "Potassium Oxalate with Fluoride",
          "type": "DEVICE"
        },
        {
          "name": "Active Comparator PO-116-A",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johnson & Johnson Consumer and Personal Products Worldwide",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2010-06",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2015-08-24",
      "last_synced_at": "2026-11-14T12:28:57.154Z",
      "location_count": 1,
      "location_summary": "Fort Wayne, Indiana",
      "locations": [
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156376"
    }
  ]
}